The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000568314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/04/2026
Date registered
Help: Date registered
5/05/2026
Date last updated
Help: Date last updated
5/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/05/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Efficacy of using over the counter oral lozenges to block the 'cold sensor' receptor to manage postnasal drip and mucous symptoms.
Scientific title
Effect of thermoreceptor transient receptor potential melastatin-8 (TRPM8) modification as a strategy for the management of adult patients with persistent postnasal drip and mucus symptoms.
Additional trial identifiers [1] 316980 0
Not applicable
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Persistent postnasal drip 341310 0
Persistent mucus symptoms 341311 0
Condition category
Condition code
Respiratory 337382 337382 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will be provided with a week supply of each oral lozenge type, readily available on the market, with a honey lemon flavor and containing either high (21 mg), low (7 mg) or no menthol at baseline clinic visit, The order of the lozenge type administration will be pre-determined at baseline (ether: 1: high, low, placebo; OR 2: high, placebo, low; OR 3: low, high, placebo; OR 4: low, placebo, high; OR 5: placebo, high, low; OR 6: placebo, low, high) and self-administered by participants every 2 hours or as needed daily for 7 days, with a washout period of 7 days, The process is then repeated for the remaining two lozenge types, with a total of 6 weeks duration for the entire study (i.e. inclusive of treatment and washout periods). At the end of each week, participants will complete a quick online questionnaire that will assess their lozenge adherence and symptoms. A study investigator will be in contact with participants on a weekly basis via email or over the phone to clarify questions and monitor progress.
Intervention code [1] 333602 0
Treatment: Drugs
Description of the comparator or control
Participants will be their own control when using the placebo lozenge (cross over trial). The placebo lozenge will be honey lemon flavored and without menthol supplied as one of the sets given to the participants during their baseline clinic visit.
Control group
Placebo

Outcomes
Primary outcome [1] 344897 0
Changes in post-nasal drip and mucus symptom severity (composite outcome).
Timepoint [1] 344897 0
Every 7 days for 6 weeks
Primary outcome [2] 345167 0
Changes in post-nasal mucus baseline severity.
Timepoint [2] 345167 0
Every 7 days for 6 weeks
Primary outcome [3] 345168 0
Changes in throat clearing severity.
Timepoint [3] 345168 0
Every 7 days for 6 weeks
Secondary outcome [1] 460739 0
Changes in lumpiness sensation severity (primary outcome).
Timepoint [1] 460739 0
Every 7 days for 6 weeks
Secondary outcome [2] 460740 0
Changes in cough severity (primary outcome).
Timepoint [2] 460740 0
Every 7 days for 6 weeks
Secondary outcome [3] 460741 0
Changes in overall symptom severity (primary outcome).
Timepoint [3] 460741 0
Visual analogue scale (VAS) scores for overall symptom severity (VAS 0-100).

Eligibility
Key inclusion criteria
Adult patients with a strong and persistent sensation of post-nasal mucus, throat clearing, lumpiness and cough despite active allergy and reflux management.
Body weight: A minimum body weight >=40 kilograms (kg) at enrolment.
Gender: Male or female.
Informed consent: Capable of giving signed written informed consent and willingness to participate to and comply with the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Diagnosis with active sinus or lung disease.
Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
History of diabetes mellitus or intolerance to trace amounts of milk, almond, peanut, macadamia or soy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
Descriptive data and comparative data analysis will be performed to evaluate outcomes of different lozenge use in the postnasal drip and mucus symptoms management.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321492 0
Charities/Societies/Foundations
Name [1] 321492 0
Rhinology and Skull Base Research trust fund
Country [1] 321492 0
Australia
Primary sponsor type
Individual
Name
Richard Harvey - Head of the Rhinology and Skull Base Research Group at St Vincent's Centre for Applied Medical Research
Address
Country
Australia
Secondary sponsor category [1] 324377 0
None
Name [1] 324377 0
Address [1] 324377 0
Country [1] 324377 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320026 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 320026 0
Ethics committee country [1] 320026 0
Australia
Date submitted for ethics approval [1] 320026 0
28/07/2025
Approval date [1] 320026 0
28/01/2026
Ethics approval number [1] 320026 0
2025/PID01744

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149186 0
Prof Richard Harvey
Address 149186 0
St Vincent's Centre for Applied Medical Research, 67 Burton St, Darlinghurst NSW 2010
Country 149186 0
Australia
Phone 149186 0
+61293604811
Fax 149186 0
Email 149186 0
Contact person for public queries
Name 149187 0
Amal Elhage
Address 149187 0
St Vincent's Centre for Applied Medical Research, 67 Burton St, Darlinghurst NSW 2010
Country 149187 0
Australia
Phone 149187 0
+61293604811
Fax 149187 0
Email 149187 0
Contact person for scientific queries
Name 149188 0
Raquel Alvarado
Address 149188 0
St Vincent's Centre for Applied Medical Research, 67 Burton St, Darlinghurst NSW 2010
Country 149188 0
Australia
Phone 149188 0
+61293604811
Fax 149188 0
Email 149188 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.